首页 | 本学科首页   官方微博 | 高级检索  
     

脐血单个核细胞和脐带间充质干细胞治疗儿童孤独症的安全性与有效性
引用本文:刘 敏,吕涌涛,郇 英,葛汝村,张 隽,姜 舒,郭传琴,胡 祥,陈兴旺,罗朝霞,安 蕾. 脐血单个核细胞和脐带间充质干细胞治疗儿童孤独症的安全性与有效性[J]. 中国组织工程研究, 2011, 15(23): 4359-4362. DOI: 10.3969/j.issn.1673-8225.2011.23.041
作者姓名:刘 敏  吕涌涛  郇 英  葛汝村  张 隽  姜 舒  郭传琴  胡 祥  陈兴旺  罗朝霞  安 蕾
作者单位:山东省交通医院,康复医学科,神经内科,细胞治疗中心,山东省济南市 250031;深圳市北科细胞工程研究所,广东省深圳市 518057;山东省精神卫生中心,山东省济南市 250014
基金项目:北京吴祖泽科技发展基金;山东省交通厅立项课题(2009Z41-4)。
摘    要:背景:目前国内外尚没有治疗儿童孤独症的金标准,康复治疗效果不佳。目的:评价脐血单个核细胞和脐带间充质干细胞治疗儿童孤独症的临床安全性和有效性。方法:37例儿童孤独症患者非随机分为脐血组、混合组和对照组。脐血组应用脐血单个核细胞加康复训练治疗;混合组联合应用脐血单个核细胞和脐带间充质干细胞加康复训练治疗;对照组单纯行康复训练治疗。脐血组和混合组患者在干细胞治疗前和首次治疗后1,2,6个月分别行相关指标实验室检查,并观察有无不良反应发生。3组患者在治疗前和首次治疗后1,2,6个月分别行儿童孤独症评定量表(CARS)和异常行为量表(ABC)评估。结果与结论:脐血组和混合组患者在干细胞治疗前和首次治疗后1,2,6个月相关指标实验室检查未发现有意义异常变化,干细胞治疗后无严重不良反应发生;根据CARS和ABC评分,3组治疗均有效,其疗效比较:混合组优于脐血组,脐血组优于对照组。

关 键 词:儿童孤独症  脐血单个核细胞  脐带间充质干细胞  安全性  有效性  
收稿时间:2011-03-14

Safety and efficacy of cord blood mononuclear cells and umbilical cord mesenchymal stem cells therapy for childhood autism
Liu Min,Lü Yong-tao,Huan Ying,Ge Ru-cun,Zhang Jun,Jiang Shu Guo Chuan-qin,Hu Xiang,Chen Xing-wang,Luo Zhao-xia,An Lei. Safety and efficacy of cord blood mononuclear cells and umbilical cord mesenchymal stem cells therapy for childhood autism[J]. Chinese Journal of Tissue Engineering Research, 2011, 15(23): 4359-4362. DOI: 10.3969/j.issn.1673-8225.2011.23.041
Authors:Liu Min  Lü Yong-tao  Huan Ying  Ge Ru-cun  Zhang Jun  Jiang Shu Guo Chuan-qin  Hu Xiang  Chen Xing-wang  Luo Zhao-xia  An Lei
Affiliation:Department of Rehabilitation Medicine, Shandong Jiaotong Hospital, Jinan  250031, Shandong Province, China; Department of Neurology, Shandong Jiaotong Hospital, Jinan  250031, Shandong Province, China; Cell Rescue Center of Shandong Jiaotong Hospital, Jinan  250031, Shandong Province, China; Shenzhen Beike Cell Engineering Research Institute, Shenzhen  518057, Guangdong Province, China; Shandong Mental Health Center, Jinan  250014, Shandong Province, China
Abstract:BACKGROUND:There is no clear standard for curing autism, and the effect of rehabilitation treatment is not satisfied. OBJECTIVE:To evaluate the safety and efficacy of cord blood mononuclear cells (MNCs) and umbilical cord mesenchymal stem cells (MSCs) in treating autistic children.METHODS:Thirty-seven children with autism were divided into MNCs treatment (MNCs plus rehabilitation treatment), MNCs combined with MSCs treatment (MNCs combined with MSCs plus rehabilitation treatment) and control (rehabilitation treatment alone) groups. Related laboratory examinations were performed for each group before treatment, 1, 2 and 6 months after treatment to observe adverse effects. Childhood Autism Rating Scale and Aberrant Behavior Checklist were employed to assess the children of autism. RESULTS AND CONCLUSION:There was no statistical difference between MNCs treatment group and MNCs combined with MSCs treatment group in laboratory examinations at each time point, and no adverse effects were observed in two groups. Childhood Autism Rating Scale and Aberrant Behavior Checklist showed that three treatment presented efficacy, but the MNCs combined with MSCs treatment group was the best, followed by MNCs treatment group, and then control group.
Keywords:
点击此处可从《中国组织工程研究》浏览原始摘要信息
点击此处可从《中国组织工程研究》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号